Fig. 2

Feasibility was evaluated by a number of days from biopsy to DNA/RNA sequencing, analysis and report, tumor board decision, and the start of MGT. The average number of days from biopsy to these time points among the three tumor types is noted in the timeline. The ranges for the means are noted in the corresponding table. Values were calculated for all subjects who met the safety criteria (n = 144). For subjects still in therapy by the time of submission, November 1, 2019, was used as the end of therapy date, so as to not exclude these subjects from evaluation. *End of therapy is defined as the number of days from biopsy to the last dose of study drug administration